Search results “French drug generic lipitor”
Lipitor becoming available as generic drug
Lipitor becoming available as generic drug
Views: 289 Lowell Sun
Fast food: Do you want fries with that Lipitor?
Subscribe to Dr. Greger’s free nutrition newsletter at https://www.nutritionfacts.org/subscribe and get a free recipe from his new HOW NOT TO DIE COOKBOOK. (All proceeds Dr. Greger receives from the sales of his books, DVDs, and speaking engagements go to support the 501c3 nonprofit that runs NutritionFacts.org.) DESCRIPTION: Cardiologists suggest that cholesterol-lowering statin drugs be given out free with fast food meals. Have a question about this video? Leave it in the comment section at http://nutritionfacts.org/videos/fast-food-do-you-want-fries-with-that-lipitor/ and I'll try to answer it! Please feel free to post any ask-the-doctor type questions here in the comments section and I'd be happy to try to answer them. Be sure to check out all the videos on heart disease (http://nutritionfacts.org/topics/heart-disease/) and statins (http://nutritionfacts.org/topics/statins/). And check out my associated blog post "Generic Lipitor is not the answer to our heart disease epidemic." (http://nutritionfacts.org/blog/2011/12/23/generic-lipitor-is-not-the-answer-to-our-heart-disease-epidemic/) http://www.NutritionFacts.org • Subscribe: http://www.NutritionFacts.org/subscribe • Donate: http://www.NutritionFacts.org/donate • HOW NOT TO DIE: http://nutritionfacts.org/book • Facebook: http://www.facebook.com/NutritionFacts.org • Twitter: http://www.twitter.com/nutrition_facts • Instagram: http://instagram.com/nutrition_facts_org/ • Google+: https://plus.google.com/+NutritionfactsOrgMD • Podcast: http://nutritionfacts.org/audio/
Views: 15011 NutritionFacts.org
Inside the Indian Generic Drug Manufacturer Cipla
India produces over 30% of the world's entire supply of generic drugs. Cipla is one of India's largest drug manufacturers. It supplies antiretroviral drugs to about one third of AIDS patients under treatment in Africa. C&EN Senior Correspondent Jean-François Tremblay went inside Cipla's advanced pharmaceutical ingredient manufacturing plant to learn more about the stringent regulations it must follow. India's future as the world's drugstore is a controversial topic. Other drugmakers have been heavily fined, or had products recalled or banned, because of problems at plants. And India is under pressure to make its patent system more like those in western nations. But India has found a market for low-cost drugs and that market isn't about to disappear. More at http://cenm.ag/cpla Like C&EN? Want more chemistry video goodness? Subscribe to our YouTube channel: https://www.youtube.com/user/CENonline Subscribe to C&EN to watch science videos with a focus on chemistry, and to hear from the researchers behind it all. -- Looking for C&EN elsewhere on the internet? Homepage: http://cen.acs.org Facebook: http://www.facebook.com/CENews Twitter: http://www.twitter.com/cenmag Tumblr: http://cenwatchglass.tumblr.com
Views: 66160 CEN Online
Shocking Before and After Fitness Transformation in 5 Hours EXPOSED! | Furious Pete
SUBSCRIBE ►http://bit.ly/Sub2FuriousPete NEW Furious Apparel ►http://FuriousApparel.com | My Supplements: http://FuriousFormulations.com 60 DAY REAL VIDEO TRANSFORMATION: https://www.youtube.com/playlist?list=PLQdB5cnMHAqeXijdy0mPmU-PrOwFTL7N2 What 'Before and Afters' can REALLY look like behind the scenes! Get REAL Workout Programs to get REAL results ►http://coaching.furiouspete.com Subscribe to My Vlogs! ► http://bit.ly/SubFuriousTalks Check Out Some of My Most Popular Videos Here: Burrito Eat Off vs Girlfriend ►https://youtu.be/PY4f_yHA2d8 Furious World Tour – Germany ►https://youtu.be/w7UDGVo6Glg 200 Wings Q&A w/ Furious Pete ►https://youtu.be/Y_ruvq7Ft9c One Man. Three Bottles of Lemon Juice ►https://youtu.be/lxlJrMRkfEw 200 Wings Q&A w/ Furious Pete ►https://youtu.be/Y_ruvq7Ft9c See Videos Early ►http://www.vessel.com/furiouspete Follow Me!! Facebook ► http://www.facebook.com/Furiouspete123 Periscope ► FuriousPete Instagram ► http://www.instagram.com/furiouspete SnapChat ► Furiouspete123 Tumblr ► http://furiouspete.tumblr.com/ Bodyspace ► http://bodyspace.bodybuilding.com/Dedicatedforlif/ Google+ ► http://gplus.to/furiouspete ► Furious Formulations: http://www.furiouscuts.com Check out my other Channels: Vlogs ►http://www.youtube.com/furioustalks Supplement Reviews ► http://www.youtube.com/suppsreviews The Furious Dog ► http://www.youtube.com/thefuriousdog Furious Eats ►http://www.youtube.com/furiouspete Furious GamePlay ►http://www.youtube.com/FuriousGamePlay Send cool stuff to my PO Box! Furious Pete 1801 Lakeshore Rd W Unit 6 PO Box 52559 Turtle Creek Mississauga, ON, L5J 4S6 Thanks for subscribing! For Business inquiries only: events [at] furiouspete.com Peter Czerwinski, aka 'Furious Pete', is a Professional Competitive Eater, Master in Engineering Graduate and Fitness Guru. He began doing Eating YouTube videos in 2007, which landed him into his first eating contest a year later (he has done 100 contests to date winning 85% of them). Through his online eating, breaking numerous Guinness World Records and eating contests, he has landed a number of TV spots for National Geographic, Discovery Channel, Sport Science, Travel Channel and currently hosts a show on German TV (Abenteuer Leben on Kabel Eins), doing a world eating tour. Through his difficult times and passion for fitness he aims to show the world that you can still have a good time in life, go out with friends, party it up, eat some burgers and still maintain a good and healthy physique. Stay Sexy, Stay Hungry, Get Laid my friends...and of course stay Dedicated For Life.
Views: 24495006 Furious Pete
Statins are gateway drugs for Big Pharma Take one and you’ll nee
Today's Alternative News Channel - Statins are gateway drugs for Big Pharma Take one and you’ll need four or five more prescriptions for the side effects One out of every three American adults take statins, and if you think that sounds like good news for statin manufacturers, you’re missing the bigger picture. All of Big Pharma benefits when people take statins. In fact, statins can really be thought of as gateway drugs. After all, they have so many side effects that you will likely end up taking several other medications after you start statins just to deal with them. What can happen to you if you take these dangerous drugs? They suppress your body’s immune system, rendering it less able to fight off infections. They also inhibit production of coenzyme Q10, which helps to regulate your immune and nervous system and maintain a healthy heart and blood pressure. There’s also a higher risk of neurological diseases when you take statins, with many patients reporting forgetfulness, confusion and memory loss. But don’t worry – whatever happens to you, Big Pharma has a solution for that, too! Source: https://prepareforchange.net/2017/12/10/statins-are-gateway-drugs-for-big-pharma-take-one-and-youll-need-four-or-five-more-prescriptions-for-the-side-effects/ See our playlist for additional information: POLITICS: https://www.youtube.com/playlist?list=PL3vNhMt4w_SI_yFQvfelBTllKUpszHtGt HEALTH NEWS: https://www.youtube.com/playlist?list=PL3vNhMt4w_SKrC2qOLET6ydlt3Lvx29i_ TECH AND SCIENCE STUFF: https://www.youtube.com/playlist?list=PL3vNhMt4w_SKhC5M0NKTePMwwwezcPFjL Today's Alternative News https://www.youtube.com/channel/UCV6WBPEdQPZAVddWfmk1-Dg https://youtu.be/TGZ1w_6Fu3g
News Update: Watson Gets Nod from Canadian Regulators to Market Generic Version of Pfizer's Liptor
May 20, 2010 -- Watson Pharmaceuticals (WPI) has received the green light from Canadian regulators to market a generic version of Pfizer's (PFE) drug Lipitor, the Associated Press reported. That comes on top of news yesterday that privately held generic drug maker Apotex said it would also launch a generic version of Lipitor in Canada, Reuters reported. Pfizer has said it will fight the release of that drug. Pfizer shares are down $0.38, or 2.4%, to $15.44. Watson shares are down 1.5%, or $0.65, to $43.08.
Views: 76 TradeTheTrend
Viagra! Best Commercial!
Viagra! Best Commercial!
Views: 48309725 Lawrence Cozma
Scientists Find New Tricks For Old Drugs
Today's news: Read more: https://www.npr.org/sections/health-shots/2018/07/09/625688126/scientists-find-new-tricks-for-old-drugs =============================================== Any violation of policy, community guidelines, copyright law or business cooperation please contact directly by mail: alejalep32@gmail.com
Views: 5 Today's news
Aventis, Sanofi bosses meet for direct talks
1. Various of Aventis headquarters in Paris 2. Various of Sanofi-Synthelabo headquarters in Paris 3. Exterior of building 4. Various of Florent Cespedes, European Pharmaceuticals Equity Analyst for Natexis Bleichroeder 5. SOUNDBITE (English) Florent Cespedes, European Pharmaceuticals Equity Analyst for Natexis Bleichroeder: "If a merger between Sanofi-Synthelabo and Aventis makes sense we believe that a merger between Novartis and Aventis makes more sense than ever because there is a very good fit in terms of product portfolio, R''n''D (Research and Development) portfolio between both groups and Novartis may benefit for example from the very strong diabetes franchise of Aventis with this portfolio. So it could be a very good reason to merge both groups." 6. Cutaway 7. SOUNDBITE (English) Florent Cespedes, European Pharmaceuticals Equity Analyst for Natexis Bleichroeder: "There are two conditions for Novartis to make an offer. The first one is an invitation from the Aventis supervisory board. This is already done. The second step is that the French government must remain neutral. For the time being it''s not very clear, the situation of the French government. But according to the press release of Novartis yesterday following its first quarter numbers, it seems that Novartis is making another step towards an offer. So we can assume that Novartis believes that the French government will remain neutral." 8. Various cutaways 9. SOUNDBITE (English) Florent Cespedes, European Pharmaceuticals Equity Analyst for Natexis Bleichroeder: "This is a strategical move for Aventis and Novartis. It is not only something tactical just to put pressure on Snafu to increase its offer. It''s really if Novartis makes its offer it''s to succeed and not only to put pressure on Sanofi." 10. Close shot of chemist sign 11. Wide shot of chemist 12. Medium interior shot of chemist 13. Various of Aventis/Sanofi-Synthelabo/Novartis medicines 14. Wide interior shot of chemist STORYLINE: France''s market watchdog said on Friday that a planned warrant issue by drug maker Aventis SA breaks market rules, dealing a blow to its attempts to fend off a hostile bid from smaller rival Sanofi-Synthelabo SA. In a statement, the Financial Markets Authority said the planned issue "does not conform to the principles that govern public offers." The decision, which is not binding but is likely to carry considerable weight with Aventis shareholders, undermines efforts by the Strasbourg-based company to resist Sanofi''s advances and negotiate a merger with Switzerland''s Novartis AG. It comes a day after Novartis said it has accepted Aventis'' invitation to enter into friendly merger talks, but stressed that "no assurances can be given that an agreement will be reached." Aventis had announced plans to distribute warrants to shareholders which would allow them to buy new shares at a knockdown price if Sanofi wins control of Aventis but loses a US patent challenge against Plavix, Sanofi''s best selling drug. The move was ostensibly designed to protect Aventis shareholders against the Plavix risk by handing them a bigger portion of the merged company if generic copies of the blood thinner are allowed onto the US market. But it was also widely seen as a "poison pill" intended to thwart or at least set back Sanofi''s offer and buy enough time for merger talks with Novartis to lead to a friendly deal. Poison pills are a defensive tactic usually used against hostile bidders in a takeover battle. Earlier on Friday, at the request of French Finance Minister Nicolas Sarkozy, the heads of Sanofi and Aventis held their first direct talks since Sanofi announced its hostile bid on January 26. You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/d4478e5840b293a2b05304e167a1d90d Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Views: 259 AP Archive
Mylan N.V.is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, Hertfordshire in the United Kingdom.In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients for generic drugs, and the generics business of Germany-based Merck KGaA.Through these acquisitions, Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. ---Image-Copyright-and-Permission--- About the author(s): Mylan License: Public domain ---Image-Copyright-and-Permission--- This channel is dedicated to make Wikipedia, one of the biggest knowledge databases in the world available to people with limited vision. Article available under a Creative Commons license Image source in video
Views: 1644 WikiWikiup
Pradaxa - "Every Hour"
Production Company : Rabbit Content Director : Paul Santana Editor : Rob Tortoriello Agency : Grey CD : Mark Schwatka http://madhousenyc.com -- A premiere post-production / editing house and then some -- MAD.HOUSE has been creating quality content for agencies, networks and brands for almost 20 years, including interactive, web and mobile.
Views: 607 MadHouseNYC
Pfizer Announces Plans for IPO
From Fnno.com, you're watching the Financial News Network. Pfizer announced a surprising 25% gain in profit today when reporting its second quarter earnings, making up for Lipitor sales lost to generic drugs with lower expenses. Now comes another announcement: The drug company is planning an IPO for mid-August. Pfizer will sell up to 20% of its animal-health unit in this initial public offering. According to Bloomberg, the IPO for the animal-health unit is part of Pfizer CEO Ian Read's plan to concentrate the company on producing new drugs to fill the hole now that Lipitor has lost market exclusivity. For more financial news and analysis, follow us on Twitter @FNNOnline, or check out our website at fnno.com
Obama Will Boost Biotech
Rosanne Ott, portfolio manager for the four star Alger Health Sciences Fund, says health care stocks will benefit during President Obama's first 100 days in office, especially generic drug-makers Teva and Mylan.
Pfizer's 2015 Forecast Disappoints, Crimped by Generics, Dollar
Pfizer Inc reported stronger-than-expected quarterly results as sales of vaccines and cancer drugs increased, but the company forecast 2015 earnings below Wall Street expectations, citing patent expirations and the stronger dollar. The largest U.S. drugmaker said on Tuesday that it earned $1.23 billion, or 19 cents per share, in the fourth quarter. That compared with $2.57 billion, or 39 cents per share, a year-earlier. Excluding special items, Pfizer earned 54 cents per share. according to Thomson Reuters, analysts on average expected 53 cents. http://news.yahoo.com/pfizers-2015-forecast-disappoints-crimped-generics-dollar-122728266--finance.html http://www.wochit.com
Views: 73 Wochit Business
Solvay Duphaston
Views: 139109 Imagic Productions
Spot Publicitario.
Pfizer Bribes Foreign Governments
Pfizer has been charged with bribing foreign government officials to allow less regulation on business and formula approvals.
Views: 341 freespeechtv
generic news video
today we explore the psyche of one of the most desperate people in news, not Keemstar, but muddy bat.
Views: 151 MuddyBat TV
Beximco Pharmaceuticals Ltd. How to pack medicine Atova 10
Beximco Pharma pack medicine without gloves. It is a video contain How to pack medicine in beximco pharma Atova 10 packing .
Views: 475 Beximco Pharma
Delaware Court Rules Mylan Generic Doesn't Infringe Upon AstraZeneca Patent
Mylan Inc. (NASDAQ:MYL) announced today that the U.S. District Court for Delaware has found that the company's Budesonide Capsules do not infringe upon AstraZeneca's (NYSE:AZN) patent for its Entocort EC capsules, a treatment for Crohn's disease. Mylan received final approval form the FDA for the Budesonide capsules on May 16, 2011. It is the generic version of AstraZeneca's Entocort EC capsules. It is the first generic version of the drug to be introduced in the U.S. Budesonide had sales in the U.S. of approximately $350 million for the twelve-month period ending March 31, 2011, according to IMS Health. The company reported it has 164 ANDAs pending FDA approval representing $94.2 billion in annual sales, citing IMS Health. 45 of those pending ANDAs are potential first-filer opportunities. Mylan has a potential upside of 18.4% based on a current price of $22.92 and an average consensus analyst price target of $27.13.
Views: 240 FinancialNewsOnline
Soccer on steroids
This was really stupid!
Views: 78 j91520912
VIDEO Pfizer as featured on BTV Business Television
http://www.b-tv.com - BTV - Business Television gives an overview of the world's leading bio pharmaceutical company and its multi-million dollar expansion. None of us feels 100% healthy 100% of the time, so it's no surprise that demand for medical products is substantial...and for Pfizer Canada. It's growing. Long considered one of the world's leading bio pharmaceutical companies. Pfizer is putting millions behind expanding it's operation. Pfizer Canada recently announced a $31.7 million investment in its Pfizer Global Supply Montreal manufacturing facility. The funds were put towards purchasing new state-of-the-art equipment, and to renovate the existing facilities to double its annual manufacturing capacity. The completion of the project allows the Montreal site the ability to produce more than 4.4 billion tablets of multivitamins each year, enough to fill seven Olympic-sized pools. After successfully acquiring five large companies including King Pharmaceuticals in 2011, and based on market capitalization, Pfizer has become one of the world's largest pharmaceutical companies. The company has been operating in Canada since 1953, employing close to 3,000 people and is one of Canada's strongest private health care research contributors. Pfizer Canada invests an average of $150 million in Canadian Research and Development annually, totaling more than $1 billion since the year 2000. The European Commission recently granted Pfizer marketing authorization for a drug used for the treatment of advanced renal cell carcinoma, a type of kidney cancer, and they have also won a U.S. regulatory approval of its treatment for one of the four most common types of leukemia. Recently the Supreme Court of Canada decided that Pfizer Canada's patent on Viagra is invalid, opening the door to less expensive, generic versions of the product. This is segment appears in the BTV Business Television episode that also features Verisante Technology, biOasis Technologies, CardioComm Solutions, Inc., and Avivagen. http://www.b-tv.com
Drugs in Sport, Match fixing ....Welcome to the Real World!!! speakyourtruth.com.au
Australian Sport is under fire. As the ACC finds Clubs and Players guilty of doping and match fixing with links to the Mafia. Well i say Welcome to the real world. Its no different to the Libor Scandal, climate change and many other scandals rocking the globe.
Views: nathan bray
Celebrex signed by Pfizer.
National TV ad.
Views: 1461 Paul Burke
Nestlé Acquires the Pfizer Baby Food Asset
http://blog.euromonitor.com/ Nestlé's acquisition of Pfizer's baby food asset has a global reach, states Ildiko Szakai, senior packaged food company analyst at Euromonitor. However, the main advantage of the asset is that 80% of sales generated are in emerging markets - 50% of which come from Asia Pacific. By acquiring this asset, Nestlé has not only strengthened its presence in China, but has also affirmed its position as number one in the baby food market in Asia Pacific.
What's In The News: May 10, 2012
This is what's in the news for Thursday, May 10, 2012. The Wall Street Journal reports GM (NYSE:GM) said it wants to sell a French transmission operation that employs 1,000 workers, as it moves to reduce losses in its European operations. The Wall Street Journal also reports Pfizer (NYSE:PFE), which spent over $87M in brand marketing this year after its Lipitor patent expired in November, is giving up on cholesterol-fighting drug because more generic versions will soon be going on sale. Reuters reports German Chancellor Angela Merkel rejected calls from her center-left opponents in Germany and Europe for economic stimulus policies that rely on new debt, warning that "growth on credit" would just move Europe deeper into crisis. Bloomberg reports oil dropped for a seventh day in New York, its longest stretch of declines since December 2009, as hopes for a solution to Europe's debt crisis receded, U.S. supplies rose and Chinese imports fell. Finally, Bloomberg also reports China Petroleum & Chemical (NYSE:SNP) and PetroChina (NYSE:PTR) face additional losses from processing crude after the government lowered fuel prices for the first time since October
Jim Zirin-Has Obamacare Fixed Our Broken Healthcare System?-Steven Brill
American annual healthcare spending is $3.8 trillion, a whopping 20% of GDP. Obamacare covered millions of uninsured Americans, but did nothing about spiraling costs. Steven Brill, author of the bestseller, America’s Bitter Pill-Money, Politics, Backroom Deals, and the Fight to Fix Our Broken Healthcare System, analyzes the issue and tells Jim Zirin what can be done about it.
Views: 147 JimZirinTV
Ici c'est Plavix
Views: 609 Pitié d'Or
Supreme Court Considering Law Restoring Copyright to Public Domain Works [audio]
Nov. 16 (Bloomberg Law) -- In 1994, Congress passed a law that took works that were previously in the public domain and restored their copyrights in compliance with an international convention. Golan v. Holder is a challenge to that law by filmmakers, conductors, and other artists who rely on the public domain to create their own work. Bloomberg Law's Jessica McKinney talks with Josh Block about the case which was argued before the Court on Oct. 5. Also, a review of IP developments including Facebook's patent application gets attention from a Congressional caucus, Tiffany & Co. coming to the aid of Christian Louboutin, and Lipitor's expiring patent. https://www.bloomberglaw.com Follow on Twitter: @BloombergLaw @JoshBlock560
Views: 366 Bloomberg Law
Microeconomics - Chapter 06: Elasticity: The Responsiveness of Demand and Supply
Elasticity is a measure of how much one economic variable responds to changes in another economic variable. The price elasticity of demand is the responsiveness of the quantity demanded to a change in price, measured by dividing the percentage change in the quantity demanded of a product by the percentage change in the product’s price.
Views: 460 Dr. Bill Schlosser
Midnight Trader Sector Report: Healthcare: BSN Medical, CVS Caremark, Pfizer, Merck
Health Care STOCKS ARE MIXED MONDAY MORNING with investors keeping close tabs on BSN Medical. According to the Financial Times, Montagu Private Equity LLP has hired Morgan Stanley to plan an IPO of the medical device company valued at 2 billion euros. Meanwhile, some investors are expecting windfalls for drug retailers such as CVS Caremark after patents for Pfeizer's blockbuster drugs Lipitor, for cholesterol, and blood thinner Plavix expire later this year. Most active in the healthcare sector so far on Monday is Pfizer trading down almost 1 percent, Merck & Co trading down almost 2 percent and Johnson and Johnson down a third of a percent.
Views: 521 TradeTheTrend
Mark Moyad Prostate Cancer Research Report 2017
Audio only: Mark Moyad reviews what's new in prostate cancer. JimJimJimJim chats with Mark and the Australian Advanced Prostate Cancer Support Group while lots of folk listen in around the world through AnCan.
Views: 1461 JimJimJimJim
Pharma and Biotech Industry Outlook - A look at trends and opportunities
1. Pharma and Biotech Industry Outlook A gander at patterns and opportunities in this undeniably difficult environment with an emphasis on the generics landscapeOctober 2012rbhuller@frost.com 2. Market Overview 2 3. Dreary Industry Growth Despite R&D Investment• The enormous worldwide marked pharma and biotech industry will create $1,092.0 billion in income by 2015.• Despite critical R&D interest in key territories like oncology, respiratory operators, lipid controllers, antidiabetescompounds, and antipsychotics the business is conveying just single digit top-line development. Source: Frost & Sullivan 9837 Changing Dynamics in the Pharma and Biotech Industry, June 2012. 3 4. Non specific Pharmaceuticals Market SummaryHow huge is the business sector and how quick What are current business progress and what are the outer challenges?is it developing? District: Global Generic medication incomes embody more or less 15 percent of the world pharmaceutical market and are growing 2-3 times quicker than the pharmaceutical business. United States, Germany, France, Revenue Growth ($ Billion) Rate (%) Japan, the United Kingdom, Canada, Italy, and Spain; represent 80.0 percent of the aggregate bland medication deals around the world. The developing markets, Brazil, Russia, India, China, and Turkey are2012 154.14 - anticipated that would grow 15-20 percent when contrasted with the development rates of full grown generics markets at2013 168.84 9.5 just 6-10 percent. Key restorative zones for generics infiltration incorporate cardiovascular disease,2014 183.70 8.8 oncology, rheumatology, and sicknesses of the focal sensory system. Generics cost 20-90 percent not exactly marked pharmaceuticals in this way decreasing social insurance costs. Contrasting administrative and2015 198.99 7.9 repayment forms all inclusive keep on representing a test to generics manufacturers.What are the key opportunities and dangers for this business? Which organizations are effective in this business sector and why? Opportunities Risks Company (Market Share) • Broad product offerings that span• A $150 billion business sector will be • Market solidification of generics Teva (18.0%) different sickness ranges open to generics rivalry producers through collusions, • Strategic acquisitions mergers, and acquisitions just Sandoz (10.0%) from patent expiry of blockbuster • Regulatory support from EMA, medications like Lipitor (Pfizer) and reinforce the predominant players. Mylan (6.0%) EDQM, FDA Zyprexa (Eli Lilly). • Branded pharmaceutical Watson (3.0%) organizations have created • Products are high quality• India and China are the biggest Stada Arzeimittal counter methods to counteract • Diversified portfolio incorporates market opportunities at $10.0 (2.0%) piece of the overall industry disintegration like claim to fame restorative territories billion and $26.5 billion adding to their own generics Other* (61.0%) • Efficient worldwide appropriation channels individually. inside. *Other incorporates incomes of remaining business sector members. Source: Frost & Sullivan M74E Generic Pharmaceuticals Market- A Global Analysis, December 2011. 4 5. Biosimilars Market SummaryHow enormous is the business sector and how quick What are current business progress and what are the outside challenges?is it developing? District: Global The Biologics Price Competition and Innovation Act of 2009 (BPCIA) secured a curtailed administrative pathway for the endorsement of biosimilars, will make ready into an undiscovered U.S. market Revenue Growth ($ Billion) Rate (%) which speaks to just 15 percent of the worldwide business sector. The great European administrative environment has permitted various biosimilar regards prompting 40 percent of the global2012 1,034.2 - market. The staying worldwide piece of the overall industry is driven by India and China biosimilar markets. Clinical2013 1,701.3 64.5 trial prerequisites for biosimilars are more thorough than those for routine generics and include to2014 2,798.7 64.5 advancement expenses and last evaluating. Potential incredulity to biosimilars may be overcome with unprejudiced instructive projects for doctors that pass on persuading non-inadequacy clinical data2015 4,603.8 64.5 for items from respectable organizations exceedingly experienced with biologics.What are the key opportunities and dangers for this business sector? Which organizations are fruitful in this business and why? Opportunities Risks Company (Global Market • Cost Share in 2010)• Patent expiries of blockbuster • Products with distinctive • Safety and viability information biologics display huge business organization courses may pick up Sandoz International
Views: 626 DailySlides
Naples Personal Injury Lawyer, Florida   Helios Legal Group
Call the Helios Legal Group's personal injury lawsuit hotline 24/7 at (888) 409-9144 for a free, no obligation consultation. We are here to help! UPDATE - We are now taking ovarian cancer from the use of talcum powder (baby powder) cases. Johnson & Johnson is the largest seller of the talc products in question, but there are other manufacturers. If you have used baby powder, and have developed ovarian cancer, please call us right away. Personal Injury Summary - A personal injury incident can result in serious injuries and liability for the parties involved. If the personal injury incident is bad enough, or the injuries are serious enough, it may be necessary to get a lawyer or attorney involved. It may be necessary to file a lawsuit against the person who caused the accident or injuries. If you are injured through no fault of your own, you may have a legal case or legal claim that can result in a settlement for monetary damages. The law is on your side, but there are time limits that govern how long you have to file a claim, and other restrictions. You need to consult a lawyer or attorney so that they can decide the merits of your legal case. The Helios Legal Group is here to help. Personal Injury Video Transcript - Have you or a loved one suffered a personal injury? Many people have a personal injury case and don’t even realize it. The Helios Legal Group can help you get the compensation you deserve. Personal injury cases can include: Motor Vehicle Accidents Workers' Compensation Social Security Disability Veterans Disability Medical Malpractice Birth Injuries, Birth Defects, Cerebral Palsy, and Erb’s Palsy Dangerous Drugs Defective Products Premises Liability such as Slip and Falls, and Dog Bites Mesothelioma and Asbestos Wrongful Death Railroad Worker Injuries or FELA claims If you or a loved one has suffered a personal injury in any of these areas, our experienced intake specialists are here to help you. Call our personal injury hotline for a free, no obligation consultation right now! Other personal injury cases of interest, along with common use, and issue - Zofran - control of nausea/vomiting in pregnancy - fetal birth defects Talcum Powder (Baby Powder) - female genital hygiene - ovarian cancer Xarelto - blood thinner - severe internal bleeding Testosterone / Low-T - hypogonadism (low testosterone) - cardiac problems Actos - diabetes control - bladder cancer SSRI Anti-depressants - depression control - birth defects, cardiovascular disease, suicide General Motors (GM) - ignition defect - sudden loss of power, brakes, steering, airbags Granuflo / Naturalyte - supplements for use in dialysis - alkalosis, cardiovascular injury Lipitor - high cholesterol - diabetes Morcellator - device used laproscopically to mince and evacuate cervical fibroids - uterine cancer, abdominal cancer Risperdal - schizophrenia, bipolar, autism control - development of breasts in boys Transvaginal (pelvic, surgical) mesh - pelvic organ prolapse - incontinence, abdominal pain, infection, migration, embedding Acetaminophen (Tylenol) - pain relief - liver failure Bard IVC Filters - prevent clots traveling from lower legs to lungs - migration, embedding Essure IUD - pregnancy prevention - migration, failure, adverse reactions Abilify anti-psychotic - compulsive behavior, gambling Taxotere - chemotherapy - permanent hair loss
Views: 189 Marjory Zhang
PFE Technical Stock Analysis Pfizer Options Trading
hi. Welcome back. Please take a moment to read the disclaimer. Nothing in this presentation shall constitute a recommendation to buy, or sell any security. Trading stocks and options involve risk. Today we are looking at the stock, Pfizer or P F E, Most stocks in this market trend up, because we are in a bull market, hence, higher prices. by the end of this video we want to accomplish three things. find the trend, current price, and set the target for the next three months. first. let's take a look at-the graph. we are going to look at the chart. on this presentation, we will focus on the monthly chart. can you guess which way it's trending? this specific chart indicates there is no trend. the stock is in a range between 30 dollars, and 35 dollars. Great. Let's move on. Second, let's find the last price that the stock traded at. 33 dollars, and 13 cents. finally third, let's set a price target for the next 3 months! this analysis concludes a price target of 34 dollars and 50 cents. our price is based on the range of the stock, it's also possible for the stock to test the lows of the range before going up. we believe this stock has a potential to the upside. At the moment the stock price is 15 times earnings. We believe this is low and a 20 times earnings is possible, hence, higher price. Hope you like this presentation. make sure to subscribe, and leave a comment! thanks for supporting Boo Bred! Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Fluorine is a chemical element with the symbol F and atomic number 9. It is the lightest halogen and exists as a highly toxic pale yellow diatomic gas at standard conditions. As the most electronegative element, it is extremely reactive: almost all other elements, including some noble gases, form compounds with fluorine. Among the elements, fluorine ranks 24th in universal abundance and 13th in terrestrial abundance. Fluorite, the primary mineral source of fluorine, was first described in 1529; as it was added to metal ores to lower their melting points for smelting, the Latin verb fluo meaning "flow" became associated with it. Proposed as an element in 1810, fluorine proved difficult and dangerous to separate from its compounds, and several early experimenters died or sustained injuries from their attempts. Only in 1886 did French chemist Henri Moissan isolate elemental fluorine using low-temperature electrolysis, a process still employed for modern production. Industrial synthesis of fluorine gas for uranium enrichment, its largest application, began during the Manhattan Project in World War II. This video is targeted to blind users. Attribution: Article text available under CC-BY-SA Creative Commons image source in video
Views: 1085 Audiopedia
The Russian Collusion Narrative, Episode 46
The Russian Trump collusion story as we know it all started on 4chan, an uncensored message board where anything goes. Back in early 2016, someone from the site mailed Rick Wilson, a GOP strategist, some fan-fiction about Donald Trump pissing on hookers in Russia. It was rooted in their desire to get revenge on Rick Wilson for calling Trump supporters “a bunch of childless males masturbating in their basements to anime” on a MSNBC talk show. Rick Wilson gave this “piss dossier” to Christopher Steele, an ex-Cambridge Union president, ex-M.I.6 Moscow field agent, ex-head of M.I.6’s Russia desk, and former adviser to British Special Forces on capture-or-kill ops in Afghanistan. Christopher Steele was already working on opposition research of Donald Trump for Fusion GPS co-founder Glenn Simpson. Also working on the report for Fusion GPS was Nellie Ohr, a Stanford Ph.D. whose expertise is Russian intelligence. Her husband is DOJ Deputy Attorney Bruce Ohr, who was demoted for his part in this scandal. Hillary Clinton, through her lawyers at Perkins Coie, paid Fusion GPS to do this “research” starting in April 2016. They centered the report around the fact the Russians were going to blackmail Trump and I guess make him do stuff in their favor like lift sanctions put in place by Barack Obama. This was later referred to as the “Steele Dossier”. Here’s a interesting bit of information. The Perkins Coie law firm represents Hillary Clinton, Fusion-GPS, Crowdstrike, Starbucks, Facebook, President Obama, George Soros and all of his NGOs, Amazon, and Google. That’s quite the client list. Article continued at http://www.magapodcast.com
Views: 214 Brandon Robinson
Ask Anything | On Call with the Prairie Doc | April 27th, 2017
Dr. Rick Holm, The Prairie Doc, is joined by Dr. Kelly Evans, and Dr. Jill Kruse, both with Avera Medical Group Brookings to answer any medical question our loyal home viewers may have. Learn more: https://www.PrairieDoc.org Like us on Facebook: https://www.facebook.com/ThePrairieDoc Follow us on Twitter: https://www.twitter.com/ThePrairieDoc Follow us on Instagram: https://www.instagram.com/ThePrairieDoc Pin us on Pinterest: https://www.pinterest.com/ThePrairieDoc
Views: 60 The Prairie Doc